Hodgkin lymphoma (HL), also known as Hodgkin disease, represents about 10 percent of all lymphomas. Approximately 8,100 new cases of HL are diagnosed in the United States each year. HL can occur in both children and adults, but it is most commonly diagnosed in adults. Incidence peaks in young adults between the ages of 20 and 34 years and again in older adults between the ages of 70 and 84 years. HL is characterized by the presence of very large cells called Reed-Sternberg (RS) cells, although other abnormal cell types may be present. HL usually starts in the lymph nodes; however, it often spreads from one lymph node to another and can also spread to other organs.

Common signs and symptoms of HL include swelling of the lymph nodes (which is often but not always painless), fever, night sweats, unexplained weight loss, itching, and lack of energy. While most people who have these complaints do not have HL, anyone with persistent symptoms should see a physician to make sure that lymphoma is not present.

**COMMON TYPES OF HL**

HL is divided into two main classifications: classical HL (cHL), which accounts for 93 percent of cases, and nodular lymphocyte-predominant HL. The type of HL a patient has may affect their treatment choices.

**CLASSICAL HL**

**Nodular Sclerosis cHL**

Nodular Sclerosis cHL is the most common subtype of HL, accounting for 60 to 80 percent of all cHL cases. In nodular (knot-like) sclerosis cHL, the involved lymph nodes contain RS cells mixed with normal white blood cells. The lymph nodes often contain a lot of scar tissue, which is where the name nodular sclerosis [scarring] originates. The disease is more common in women than in men, and it usually affects adolescents and adults under the age of 50 years. The majority of patients are cured with current treatments.

**Mixed Cellularity cHL**

Mixed Cellularity cHL accounts for about 15 to 30 percent of all HL cases. The disease is found more commonly in men than in women, and it primarily affects older adults. With this type of cHL, the lymph nodes contain many RS cells in addition to several other cell types. More advanced disease is usually present by the time this subtype is diagnosed.

**Lymphocyte-Rich cHL**

Lymphocyte-Rich cHL accounts for less than five percent of HL cases. The disease may be diffuse [spread out] or nodular in form and is characterized by the presence of numerous normal-appearing lymphocytes and classic RS cells. This subtype of HL is usually diagnosed at an early stage in adults and has a low relapse [disease returns after treatment] rate.

**LYMPHOCYTE-PREDOMINANT HL**

**Nodular Lymphocyte-Predominant HL**

Nodular Lymphocyte-Predominant HL accounts for seven percent of all HL cases. It affects men more often than women and is usually diagnosed before the age of 35 years. Typical RS cells are usually not found in this subtype, but large, abnormal B cells [sometimes referred to as popcorn cells] can be seen, as well as small B cells, which may be distributed in a nodular pattern within the tissues. This subtype is usually diagnosed at an early stage and is not very aggressive. This form of HL resembles indolent [slow-growing] B-cell non-Hodgkin lymphoma (NHL) and is characterized by late recurrences [that is, NHL that has returned after having disappeared for a while].

**TREATMENT OPTIONS**

The majority of patients with HL can be cured. Most patients treated for HL receive some form of chemotherapy, sometimes followed by radiation therapy, as their first treatment. Standard frontline [initial] chemotherapy for HL is ABVD [adriamycin, bleomycin, vinblastine, and dacarbazine] with or without radiation therapy or other agents, depending on the patient’s type and stage of HL as well as their overall health status. In 2018, brentuximab vedotin [Adcetris] in combination with chemotherapy was approved by the U.S. Food and Drug Administration (FDA) for frontline treatment of patients with Stage III or IV cHL. Other chemotherapy regimens may
Patients with lymphoma should have regular visits with a physician who is familiar with their medical history and the treatments they have received. Medical tests (such as blood tests and computed tomography [CT]/positron emission tomography [PET] scans) may be required at various times during remission to evaluate the need for additional treatment.

Since HL is a highly curable malignancy mostly affecting young people with long life expectancy, there is a growing number of HL survivors who may have special medical needs such as screening for secondary cancers or monitoring for long-term toxicities of therapy. Additional resources for adolescents and young adults living with cancer are available on LRF’s website at lymphoma.org/eraselymphoma.

Patients and their caregivers are encouraged to keep copies of all medical records and test results as well as information on the types, amounts, and duration of all treatments received. This documentation will be important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF’s award-winning Focus On Lymphoma mobile app [lymphoma.org/mobileapp] and Lymphoma Care Plan [lymphoma.org/publications] can help patients manage this documentation.

Clinical Trials Information Service
Clinical trials are crucial in identifying effective drugs and determining optimal doses for patients with lymphoma. Patients interested in participating in a clinical trial should view the Understanding Clinical Trials fact sheet on LRF’s website at www.lymphoma.org, talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling 800-500-9976 or emailing helpline@lymphoma.org

Education Resources
- In-Person Education Programs
- Focus on Lymphoma Mobile App
- Patient Publications
- Podcasts
- Webinars
- YouTube Videos

Support Services
- Financial Assistance Program
- LRF Helpline
- Lymphoma Support Network
- Stories of Hope

TREATMENTS UNDER INVESTIGATION

Although the cure rate in HL is already high (~75% in newly diagnosed patients), research continues to develop more effective therapies with fewer short- and long-term toxicities. Investigators are also looking for ways to treat the minority of patients who are refractory to treatment and those who relapse. Studies for relapsed/refractory HL are looking at new combinations of targeted therapies or immunotherapies including ibrutinib (Imbruvica), lenalidomide (Revlimid), and a different class of drugs called histone deacetylase (HDAC) inhibitors. Clinical trials are also ongoing for the use of ADCT-301 (camidanlumab tesirine) and anti-CD30-CAR (chimeric antigen receptor) T-cell therapy in relapsed/refractory HL.

FOLLOW-UP

Patients with lymphoma should have regular visits with a physician who is familiar with their medical history and the medical tests (such as blood tests and computed tomography [CT]/positron emission tomography [PET] scans) may be required at various times during remission to evaluate the need for additional treatment.

Since HL is a highly curable malignancy mostly affecting young people with long life expectancy, there is a growing number of HL survivors who may have special medical needs such as screening for secondary cancers or monitoring for long-term toxicities of therapy. Additional resources for adolescents and young adults living with cancer are available on LRF’s website at lymphoma.org/eraselymphoma.

Patients and their caregivers are encouraged to keep copies of all medical records and test results as well as information on the types, amounts, and duration of all treatments received. This documentation will be important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF’s award-winning Focus On Lymphoma mobile app [lymphoma.org/mobileapp] and Lymphoma Care Plan [lymphoma.org/publications] can help patients manage this documentation.

Clinical Trials Information Service
Clinical trials are crucial in identifying effective drugs and determining optimal doses for patients with lymphoma. Patients interested in participating in a clinical trial should view the Understanding Clinical Trials fact sheet on LRF’s website at www.lymphoma.org, talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling 800-500-9976 or emailing helpline@lymphoma.org

Education Resources
- In-Person Education Programs
- Focus on Lymphoma Mobile App
- Patient Publications
- Podcasts
- Webinars
- YouTube Videos

Support Services
- Financial Assistance Program
- LRF Helpline
- Lymphoma Support Network
- Stories of Hope

TREATMENTS UNDER INVESTIGATION

Although the cure rate in HL is already high (~75% in newly diagnosed patients), research continues to develop more effective therapies with fewer short- and long-term toxicities. Investigators are also looking for ways to treat the minority of patients who are refractory to treatment and those who relapse. Studies for relapsed/refractory HL are looking at new combinations of targeted therapies or immunotherapies including ibrutinib (Imbruvica), lenalidomide (Revlimid), and a different class of drugs called histone deacetylase (HDAC) inhibitors. Clinical trials are also ongoing for the use of ADCT-301 (camidanlumab tesirine) and anti-CD30-CAR (chimeric antigen receptor) T-cell therapy in relapsed/refractory HL.

FOLLOW-UP

Patients with lymphoma should have regular visits with a physician who is familiar with their medical history and the medical tests (such as blood tests and computed tomography [CT]/positron emission tomography [PET] scans) may be required at various times during remission to evaluate the need for additional treatment.

Since HL is a highly curable malignancy mostly affecting young people with long life expectancy, there is a growing number of HL survivors who may have special medical needs such as screening for secondary cancers or monitoring for long-term toxicities of therapy. Additional resources for adolescents and young adults living with cancer are available on LRF’s website at lymphoma.org/eraselymphoma.

Patients and their caregivers are encouraged to keep copies of all medical records and test results as well as information on the types, amounts, and duration of all treatments received. This documentation will be important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF’s award-winning Focus On Lymphoma mobile app [lymphoma.org/mobileapp] and Lymphoma Care Plan [lymphoma.org/publications] can help patients manage this documentation.

Clinical Trials Information Service
Clinical trials are crucial in identifying effective drugs and determining optimal doses for patients with lymphoma. Patients interested in participating in a clinical trial should view the Understanding Clinical Trials fact sheet on LRF’s website at www.lymphoma.org, talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling 800-500-9976 or emailing helpline@lymphoma.org

Education Resources
- In-Person Education Programs
- Focus on Lymphoma Mobile App
- Patient Publications
- Podcasts
- Webinars
- YouTube Videos

Support Services
- Financial Assistance Program
- LRF Helpline
- Lymphoma Support Network
- Stories of Hope